Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis: A Randomized Clinical Trial.

ABSTRACT:

Importance

Treatment options are needed for patients with rheumatoid arthritis (RA) who experience inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). The efficacy and safety profiles of subcutaneous tocilizumab monotherapy, tocilizumab combined with methotrexate, and methotrexate alone have not yet been evaluated in the same large-scale study.

Objective

To evaluate the efficacy and safety of subcutaneous tocilizumab monotherapy, tocilizumab-methotrexate, and methotrexate alone for patients with RA.

Design, setting, and participants

This double-blind, large-scale phase 3 randomized clinical trial was conducted at 19 sites in China from July 2017 through August 2022, with a 24-week double-blind treatment phase, a 24-week exte

SUBMITTER: Liu T 

PROVIDER: S-EPMC12090025 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature